CLAIMS

[Claim 1] Use of 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for improving a urination disorder,

wherein the urination disorder is at least one urination disorder selected from increased residual urine volume, reduced urination efficiency, increased bladder capacity, increased bladder wet weight and kidney wet weight, and reduced bladder contraction force.

[Claim 2] The use according to claim 1, wherein 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione or a pharmaceutically acceptable salt thereof improves at least one urination disorder or symptom selected from feeling of incomplete emptying, slow stream, hesitancy, straining, terminal dribble, post micturition dribble, urinary incontinence, frequent urination, urgency, bladder pain or bladder pain syndrome, pain on urination, cystatrophia, neurogenic bladder, detrusor overactivity or overactive bladder, chronic cystitis, interstitial cystitis, chronic prostatitis, pelvic pain syndrome, underactive bladder, and detrusor hyperactivity with

impaired contractile function.

[Claim 3] The use according to claim 1 or 2, wherein the urination disorder is a urination disorder due to or caused by benign prostatic hyperplasia.

[Claim 4] The use according to claim 1 or 2, wherein the urination disorder is a urination disorder having no benign prostatic hyperplasia.

[Claim 5] The use according to any one of claims 1 to 4, wherein the urination disorder is a bladder smooth muscle contraction disorder.

[Claim 6] The use according to any one of claims 1 to 5, wherein the urination disorder is a urination disorder caused by at least one disease selected from the following: a disease causing neurogenic bladder; diabetes; complication neuropathy in diabetes or afferent or efferent neuropathy of the micturition reflex system; hyperglycemia; and complication neuropathy in hyperglycemia.

[Claim 7] The use according to any one of claims 1 to 6, wherein a dosage of 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione or a pharmaceutically acceptable salt thereof is 0.01 to

100 mg per day in terms of 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione.